357 related articles for article (PubMed ID: 15867394)
41. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures.
Richards JO; Treisman J; Garlie N; Hanson JP; Oaks MK
Cytometry A; 2012 May; 81(5):374-81. PubMed ID: 22467596
[TBL] [Abstract][Full Text] [Related]
42. Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.
Lim E; Browning J; MacGregor D; Davis ID; Cebon JS
Melanoma Res; 2006 Aug; 16(4):347-55. PubMed ID: 16845331
[TBL] [Abstract][Full Text] [Related]
43. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients.
Schrama D; Andersen MH; Terheyden P; Schrøder L; Pedersen LO; thor Straten P; Becker JC
Cancer Res; 2001 Jan; 61(2):493-6. PubMed ID: 11212239
[TBL] [Abstract][Full Text] [Related]
44. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
Wong RM; Scotland RR; Lau RL; Wang C; Korman AJ; Kast WM; Weber JS
Int Immunol; 2007 Oct; 19(10):1223-34. PubMed ID: 17898045
[TBL] [Abstract][Full Text] [Related]
45. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
46. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy.
Trefzer U; Hofmann M; Reinke S; Guo YJ; Audring H; Spagnoli G; Sterry W
Melanoma Res; 2006 Apr; 16(2):137-45. PubMed ID: 16567969
[TBL] [Abstract][Full Text] [Related]
47. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.
Chen Q; Jackson H; Shackleton M; Parente P; Hopkins W; Sturrock S; MacGregor D; Maraskovsky E; Tai TY; Dimopoulos N; Masterman KA; Luke T; Davis ID; Chen W; Cebon J
Cancer Immun; 2005 Mar; 5():5. PubMed ID: 15755075
[TBL] [Abstract][Full Text] [Related]
48. The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients.
Cassarino DS; Miller WJ; Auerbach A; Yang A; Sherry R; Duray PH
J Cutan Pathol; 2006 May; 33(5):335-42. PubMed ID: 16640539
[TBL] [Abstract][Full Text] [Related]
49. Melanosomal targeting sequences from gp100 are essential for MHC class II-restricted endogenous epitope presentation and mobilization to endosomal compartments.
Lepage S; Lapointe R
Cancer Res; 2006 Feb; 66(4):2423-32. PubMed ID: 16489049
[TBL] [Abstract][Full Text] [Related]
50. Expression of melanoma-associated antigens in melanoma cell cultures.
Urosevic M; Braun B; Willers J; Burg G; Dummer R
Exp Dermatol; 2005 Jul; 14(7):491-7. PubMed ID: 15946236
[TBL] [Abstract][Full Text] [Related]
51. Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration.
Bartlett EK; Fetsch PA; Filie AC; Abati A; Steinberg SM; Wunderlich JR; White DE; Stephens DJ; Marincola FM; Rosenberg SA; Kammula US
Clin Cancer Res; 2014 May; 20(10):2607-2616. PubMed ID: 24647571
[TBL] [Abstract][Full Text] [Related]
52. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy.
Khong HT; Rosenberg SA
J Immunol; 2002 Jan; 168(2):951-6. PubMed ID: 11777994
[TBL] [Abstract][Full Text] [Related]
53. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.
Khong HT; Wang QJ; Rosenberg SA
J Immunother; 2004; 27(3):184-90. PubMed ID: 15076135
[TBL] [Abstract][Full Text] [Related]
54. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
55. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
56. The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer.
Fonteneau JF; Brilot F; Münz C; Gannagé M
J Immunol; 2016 Jan; 196(1):64-71. PubMed ID: 26608910
[TBL] [Abstract][Full Text] [Related]
57. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.
Klarquist J; Barfuss A; Kandala S; Reust MJ; Braun RK; Hu J; Dilling DF; McKee MD; Boissy RE; Love RB; Nishimura MI; Le Poole IC
Am J Pathol; 2009 Dec; 175(6):2463-72. PubMed ID: 19893037
[TBL] [Abstract][Full Text] [Related]
58. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
59. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
[TBL] [Abstract][Full Text] [Related]
60. Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8 + memory T cells can be detected in healthy humans.
Przybyla A; Zhang T; Li R; Roen DR; Mackiewicz A; Lehmann PV
Cancer Immunol Immunother; 2019 May; 68(5):709-720. PubMed ID: 30783693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
